Why BGPT?
logo

Check Your Claims Before Reviewers Do

Verify your claims against versioned evidence records with exact reported results and sources.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims



    Explore by Goal












     Quick Explanation


    Author review (evidence-bounded)
    Based only on the bibliometric + title list you provided (no external paper metadata/DOIs were available to verify claims), Grimminger’s publication output appears broad across pulmonary vascular biology, lung inflammation, and lung tumor microenvironment, including both mechanistic and clinical/registry-scale work.
    Key limitation: without DOIs/full texts for each listed item, I can’t independently verify study designs, effect sizes, endpoints, sample sizes, or replication status.



     Long Explanation


    Author Review: Friedrich Grimminger
    Science-focused, skeptical, evidence-bounded critique using only the bibliometric values and paper titles you supplied.
    Provided bibliometrics (from your dataset)
    h-index
    40
    Indicator of citation accrual breadth over time.
    Total citations
    7138
    Raw citation count; sensitive to field size & longevity.
    Paper count
    107
    High output correlates with wider topic coverage (but not proof of rigor).
    Bibliometrics visualization (input-derived)
    Note: citation metrics do not encode experimental rigor, reproducibility, or causal validity; they only summarize scholarly impact.
    Topic coverage proxy (from titles only)
    I grouped titles into coarse buckets using only visible keywords/phrases in the titles you provided (not abstract content).
    Important limitation: this figure is only a title-keyword proxy. Many titles are clinical/registry-like while others are mechanistic, but without DOIs/full texts I cannot confirm the proportion accurately.
    Scientific strength signals (what the provided record suggests)
    1) Breadth across connected lung systems
    The title list you provided includes repeated themes: pulmonary hypertension/hemodynamics, lung inflammation (e.g., NO/ROS/endotoxin), lung cancer biology (immune landscapes, tumor microenvironment), and lung injury/COPD/emphysema models.
    2) Translational bridge (mechanistic ↔ clinical/registry)
    You supplied multiple titles that are mechanistic (e.g., pericyte inflammation, iNOS inhibition, mitochondrial/ROS pathways, channel mechanisms) and also titles that look like prospective studies, meta-registry analyses, and survival association work.
    3) Potential methodological diversity
    Titles include imaging/AI elements (AI-CNN on micro-CT), spatial immune landscapes, and histopathology/EBUS-guided procedures—suggesting comfort with multiple modalities.
    Skeptical note: the strongest assessment of scientific rigor would require verifying (i) study design, (ii) effect sizes and confidence intervals, (iii) sample sizes and power, (iv) blinding/randomization, (v) independent replication, and (vi) whether mechanistic claims are causally supported. None of these can be confirmed from titles alone.
    Critical blind spots & error sources (what could mislead you)
    • Title-based misclassification: keyword buckets can over/under-estimate topic proportions and can’t tell you whether a paper is observational vs interventional, or exploratory vs confirmatory.
    • Citation-metric confounding: h-index and total citations are influenced by field size, collaboration networks, and publication venue—not only rigor or truthfulness.
    • Publication and reporting bias risks: without full-text access, you can’t assess whether null/negative replications exist or whether selective reporting occurred.
    • Species/translation differences: titles suggest both human and animal work; translation success often varies by model system.
    • Causal vs associative claims: registry/survival titles may be confounded; mechanistic titles may be correlational unless causal perturbations and appropriate controls are shown.
    What would most improve/disconfirm this author-quality assessment
    Would strengthen rigor score if you can verify
    • Clear causal mechanisms supported by well-controlled perturbations (genetic/chemical/physiological) plus appropriate negative/positive controls.
    • Independent replication across labs/centers and consistent effect directions.
    • For clinical/registry work: adjustment for known confounders and transparent handling of missingness; ideally sensitivity analyses.
    Would lower rigor/credibility if you find
    • Inadequate controls/blinding or weak causal inference for mechanistic claims.
    • Non-reproducible imaging/AI findings without external validation sets.
    • Overstated mechanistic generalization from single-model systems.
    • Association ≠ causation problems in registry analyses without robust confounding control.
    If you paste DOIs or provide full texts/PDFs for a subset of the listed papers, I can convert this into a true evidence-grade review (study design critique, endpoint validity, statistical rigor, and replication checks).
    Paper-title inventory (subset view)
    Your message lists many papers; below is a compact table of the first N titles you provided (as visible). This is not a completeness claim.
    Title Visible cue (from title)
    Divergent CD45+ immune landscapes shape the lung tumor microenvironment.Immune landscapes / tumor microenvironment
    Mitochondrial COX4I2 drives pericyte-dependent inflammation and emphysemaMitochondria / pericytes / emphysema
    Right Ventricular Response to Pulmonary Hypertension: Sex- and Strain-Dependent Differences in Sugen5416 and Hypoxia ModelsRV / PAH models / sex & strain
    Exercise haemodynamics in pulmonary hypertension – a prospective pressure–volume loop study on right ventricular adaptation and prognosisHemodynamics / prospective PV loops
    Living human lung slices for ex vivo modelling of lung cancerEx vivo human lung slices / cancer
    Microscopic computed tomography with AI-CNN powered image analysis: the path to phenotype the bleomycin-induced pulmonary injury.AI-CNN / micro-CT / bleomycin injury
    Non-invasive surrogate markers of pulmonary hypertension are associated with poor survival in patients with cancerAssociations / survival
    Hypoxic vasoconstriction: a multifactorial response?Hypoxic vasoconstriction / mechanistic framing
    Next step (if you want a true evidence-grade review)
    Provide DOIs or PDFs for 5–15 representative papers (e.g., 3 mechanistic, 3 clinical/registry, 2 AI/imaging, 2 translational). I can then assess methods, causality, statistics, and replication—rather than relying on titles + bibliometrics.


    Feedback:    

    Updated: April 01, 2026

     BGPT Author Review


    Scientific Quality

    60%

    From the provided record alone, the author appears productive (107 papers) and broadly impactful (h-index 40; 7138 citations). However, scientific quality and rigor cannot be validated from titles and aggregate metrics: we lack DOIs/full texts to check causal design, controls, blinding, statistical power, robustness/sensitivity analyses, external validation (for AI/imaging), and replication. Therefore, I rate quality as moderate-to-good on “likely breadth/impact,” with a major uncertainty penalty for missing method-level evidence.


    Communication Quality

    60%

    Communication quality cannot be judged from titles and bibliometrics. The title set suggests topic clarity and thematic coherence (lung immunobiology/PH/CT/AI), but I can’t assess writing structure, interpretability, or whether conclusions match evidence without abstracts/full text.


    Author Novelty

    50%

    The themes suggest established but actively developed areas (pulmonary hypertension and lung inflammation mechanisms). Novelty is unknowable without reading methods/claims and checking whether approaches are genuinely new versus incremental within those fields.


    Scientific Rigor

    50%

    Rigor cannot be directly scored without study design and statistical details. The presence of prospective/registry/imaging/AI titles suggests potentially rigorous methods, but titles alone don’t reveal confounder control, blinding/randomization, model validation, effect sizes, or reproducibility practices.

     Analysis Wizard



    Parses your provided title list into keyword buckets, builds topic-frequency tables, and generates Plotly charts summarizing coverage; then exports a CSV for your own DOI/PDF attachment workflow.



     Hypothesis Graveyard


    “Imaging signatures directly prove underlying pathway causation.” Titles can’t establish causality; without perturbation experiments and external validation, strong causal claims should be retired.


    “Registry survival associations imply targeted therapy causal benefit across all PAH phenotypes.” Without confounder/sensitivity analyses and phenotype stratification details, such generalizations are fragile and can fail in alternate cohorts.

     Science Art


    Author Review: Friedrich Grimminger Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending